Removing barriers to tecovirimat treatment for individuals infected with mpox via a novel care delivery model.

Publication/Presentation Date

1-1-2026

Abstract

OBJECTIVE: This study analyzed the care delivery of a new clinic model designed to provide access to an investigational new drug (IND) during the 2022 mpox outbreak at a single academic quaternary care center.

METHODS: A dedicated tecovirimat referral clinic was created and staffed by a physician associate (PA) trained in IND protocol. The PA assessed patients via telemedicine, managed IND paperwork, prescribed tecovirimat and arranged for its home delivery, and monitored drug tolerance.

RESULTS: Of 35 patients referred to the clinic, 17 received tecovirimat. Mean time from clinic referral to first mpox provider visit was 1.03 days (SD = 1.90) and from first mpox provider visit to tecovirimat receipt was 0.22 days (SD = 0.43). Time before referral was notably longer, with a mean of 9.37 days (SD = 4.81) between symptom onset and referral.

CONCLUSIONS: This clinic provided timely, efficient, specialized care for patients with suspected infection despite the practical barriers of IND protocol.

Volume

39

Issue

1

First Page

5

Last Page

5

ISSN

1547-1896

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

PubMedID

41433123

Department(s)

Administration and Leadership

Document Type

Article

Link to Full Text

Share

COinS